$0.9741
Revenue is up for the last 2 quarters, 31.0K → 32.0K (in $), with an average increase of 3.1% per quarter
Netprofit is up for the last 4 quarters, -23.64M → -12.40M (in $), with an average increase of 27.7% per quarter
In the last 1 year, Seagen Inc has given 39.6% return, outperforming this stock by 123.6%
In the last 3 years, Moderna Inc has given 26.0% return, outperforming this stock by 124.7%
3.62%
Downside
Day's Volatility :9.23%
Upside
5.83%
48.13%
Downside
52 Weeks Volatility :95.21%
Upside
90.76%
Period | Athersys Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -36.33% | 0.9% | -8.3% |
6 Months | 60.0% | -6.8% | -6.5% |
1 Year | -83.97% | 0.4% | -6.1% |
3 Years | -98.66% | 27.3% | 21.8% |
Market Capitalization | 20.5M |
Book Value | - $1.68 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -4.02 |
PEG Ratio | -0.34 |
Wall Street Target Price | 5.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -2151.26% |
Return On Assets TTM | -97.44% |
Return On Equity TTM | -1276.02% |
Revenue TTM | 2.4M |
Revenue Per Share TTM | 0.17 |
Quarterly Revenue Growth YOY | -95.7% |
Gross Profit TTM | -65.6M |
EBITDA | -50.7M |
Diluted Eps TTM | -4.02 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.05 |
EPS Estimate Next Year | -0.7 |
EPS Estimate Current Quarter | -0.54 |
EPS Estimate Next Quarter | -0.48 |
What analysts predicted
Upside of 464.62%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 3.7M | ↓ 78.62% |
Net Income | -32.2M | ↑ 110.22% |
Net Profit Margin | -869.5% | ↓ 781.09% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 24.3M | ↑ 555.1% |
Net Income | -24.3M | ↓ 24.68% |
Net Profit Margin | -99.97% | ↑ 769.53% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 5.6M | ↓ 76.81% |
Net Income | -44.6M | ↑ 83.59% |
Net Profit Margin | -791.44% | ↓ 691.47% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.4M | ↓ 74.44% |
Net Income | -78.8M | ↑ 76.67% |
Net Profit Margin | -5.5K% | ↓ 4678.35% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 5.5K | ↓ 99.62% |
Net Income | -87.0M | ↑ 10.4% |
Net Profit Margin | -1.6M% | ↓ 1571516.06% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 5.3M | ↑ 96472.36% |
Net Income | -72.5M | ↓ 16.58% |
Net Profit Margin | -1.4K% | ↑ 1575623.71% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | -4.1K | ↓ 184.93% |
Net Income | -21.7M | ↑ 34.21% |
Net Profit Margin | 533.4K% | ↑ 871023.27% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.9M | ↓ 71647.91% |
Net Income | -22.2M | ↑ 2.33% |
Net Profit Margin | -762.91% | ↓ 534202.71% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.3M | ↓ 20.47% |
Net Income | -23.6M | ↑ 6.45% |
Net Profit Margin | -1.0K% | ↓ 258.16% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 65.0K | ↓ 97.19% |
Net Income | -13.7M | ↓ 42.2% |
Net Profit Margin | -21.0K% | ↓ 20008.16% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 31.0K | ↓ 52.31% |
Net Income | -13.0M | ↓ 4.89% |
Net Profit Margin | -41.9K% | ↓ 20909.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 32.0K | ↑ 3.23% |
Net Income | -12.4M | ↓ 4.59% |
Net Profit Margin | -38.8K% | ↑ 3176.21% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 33.6M | ↑ 76.25% |
Total Liabilities | 10.2M | ↑ 29.67% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 61.7M | ↑ 83.76% |
Total Liabilities | 18.6M | ↑ 82.19% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 41.7M | ↓ 32.5% |
Total Liabilities | 18.4M | ↓ 1.18% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 59.7M | ↑ 43.32% |
Total Liabilities | 28.4M | ↑ 54.13% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 60.2M | ↑ 0.79% |
Total Liabilities | 43.8M | ↑ 54.54% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 27.7M | ↓ 53.92% |
Total Liabilities | 51.6M | ↑ 17.73% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 60.2M | ↓ 16.51% |
Total Liabilities | 43.8M | ↑ 2.51% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 45.0M | ↓ 25.3% |
Total Liabilities | 44.7M | ↑ 1.91% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 35.2M | ↓ 21.7% |
Total Liabilities | 46.9M | ↑ 5.13% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 35.5M | ↑ 0.96% |
Total Liabilities | 52.2M | ↑ 11.11% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 27.7M | ↓ 21.98% |
Total Liabilities | 51.6M | ↓ 1.1% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 27.7M | ↑ 0.0% |
Total Liabilities | 51.6M | ↑ 0.0% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -24.0M | ↑ 119.72% |
Investing Cash Flow | -285.0K | ↓ 73.29% |
Financing Cash Flow | 38.9M | ↑ 943.66% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.4M | ↓ 44.42% |
Investing Cash Flow | -915.0K | ↑ 221.05% |
Financing Cash Flow | 36.0M | ↓ 7.35% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -35.3M | ↑ 164.61% |
Investing Cash Flow | -579.0K | ↓ 36.72% |
Financing Cash Flow | 19.9M | ↓ 44.77% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -61.8M | ↑ 74.97% |
Investing Cash Flow | -1.2M | ↑ 100.69% |
Financing Cash Flow | 79.5M | ↑ 299.64% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -76.2M | ↑ 23.26% |
Investing Cash Flow | -1.4M | ↑ 17.04% |
Financing Cash Flow | 63.4M | ↓ 20.22% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -19.3M | ↓ 47.39% |
Investing Cash Flow | -206.0K | ↓ 47.98% |
Financing Cash Flow | 7.3M | ↓ 83.06% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -20.2M | ↑ 4.31% |
Investing Cash Flow | -186.0K | ↓ 9.71% |
Financing Cash Flow | 4.7M | ↓ 34.8% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -16.4M | ↓ 18.49% |
Investing Cash Flow | -1.6M | ↑ 781.18% |
Financing Cash Flow | 9.7M | ↑ 103.58% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.4M | ↓ 36.83% |
Investing Cash Flow | -178.0K | ↓ 89.14% |
Financing Cash Flow | 11.0M | ↑ 13.54% |
Sell
Neutral
Buy
Athersys Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Athersys Inc | 27.02% | 60.0% | -83.97% | -98.66% | -98.56% |
![]() Moderna, Inc. | 0.28% | -25.82% | -4.84% | 117.92% | 601.67% |
![]() Regeneron Pharmaceuticals, Inc. | -7.87% | -2.05% | 17.39% | 22.45% | 137.1% |
![]() Seagen, Inc. | -1.61% | 61.18% | 39.62% | 26.01% | 217.64% |
![]() Vertex Pharmaceuticals Incorporated | -3.63% | 5.09% | 23.88% | 20.49% | 123.04% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Athersys Inc | 0.72 | NA | -0.34 | -1.05 | -12.76 | -0.97 | 0.0 | -1.68 |
![]() Moderna, Inc. | 11.46 | 11.46 | 0.0 | -1.9 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.91 | 19.91 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.18 | 26.18 | 0.41 | 14.61 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Athersys Inc | Buy | $20.5M | -98.56% | 0.72 | 0.0% |
![]() Moderna, Inc. | Buy | $49.1B | 601.67% | 11.46 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $80.7B | 137.1% | 19.91 | 33.81% |
![]() Seagen, Inc. | Hold | $36.5B | 217.64% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $83.3B | 123.04% | 26.18 | 35.4% |
Vahanian & Associates Financial Planning Inc.
BlackRock Inc
Vanguard Group Inc
Renaissance Technologies Corp
Geode Capital Management, LLC
SIMPLEX TRADING, LLC
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived 'off-the-shelf' stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization.
Organization | Athersys Inc |
Employees | 24 |
CEO | Mr. Daniel A. Camardo M.B.A. |
Industry | Health Technology |
Marathon Digital Holdings Inc
$10.03
+0.4%
MARBLEGATE ACQUISITION CORP.
$10.18
+0.0%
BLACK MOUNTAIN ACQUISITION-A
$10.55
+0.0%
BLOCKCHAIN COINVESTORS ACQUISITION CORP.
$10.51
+0.29%
IQ CHAIKIN US LARGE CAP ETF
$31.64
-0.03%
LARGO RESOURCES LTD
$3.82
+0.53%
LUTHER BURBANK CORP
$9.39
+6.58%
Standard Motor Products Inc
$37.12
+3.66%
Anfield Capital Diversified Alternatives ETF
$8.36
+1.7%